Brokerage : Yuanta Securities
Analyst : Hyunsoo Ha
Investment Rating : BUY (Maintained)
Target Price : KRW 2,100,000 (Maintained)
Core Momentum : Finalization of the US Maryland facility acquisition and anticipated Biosecure Act beneficiary orders drive earnings upside, complemented by Plant 6 groundbreaking and next-generation modality expansions at Bio Campus 3.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 2,100,000 (Maintained) (Previous Target Price: KRW 2,100,000; upside potential of 34% based on the April 1, 2026 closing price of KRW 1,572,000)
- Market Data: Market Cap KRW 72.77 Trillion / Total Shares Outstanding 46,290,951 / 60-Day Average Trading Value KRW 99.9 Billion / Foreign Ownership 12.73% / Dividend Yield 0.00% / Major Shareholders: Samsung C&T and 5 affiliates
- Annual Financial Forecast (K-IFRS Standalone Estimates):
- 2026F: Revenue KRW 5.41 Trillion, Operating Profit KRW 2.41 Trillion, Net Profit (Controlling) KRW 1.89 Trillion, PER 38.4x, PBR 7.8x, EV/EBITDA 25.1x, ROE 22.7%
- 2027F: Revenue KRW 6.05 Trillion, Operating Profit KRW 2.74 Trillion, Net Profit (Controlling) KRW 2.21 Trillion, PER 32.9x, PBR 6.3x, EV/EBITDA 21.8x, ROE 21.2%
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Preview:
- Standalone/consolidated revenue is projected at KRW 1.26 Trillion (+26.5% YoY) and operating profit at KRW 558.7 Billion (+29.9% YoY, OPM 44.2%), with revenue tracking 1.1% above consensus and operating profit tracking 1.6% below consensus.
- Solid earnings growth is driven by the top-line recognition of deferred Q4 2025 production batches and full utilization across Plants 1 through 4.
- Plant 5 is scheduled to commence initial revenue recognition in Q2 2026, with full-scale commercial contributions beginning in 2027.
- US Maryland Facility Acquisition & Guidance Upside:
- Finalized the acquisition of GSK’s 60,000-liter manufacturing facility in Maryland on March 31. The total acquisition cost of USD 350 Million consists of the plant purchase price (USD 280 Million) and raw material/inventory transfer costs (USD 70 Million).
- Retention of the local workforce enables production start in Q2 2026, with commercial revenue recognition set for Q3 2026.
- Inclusion of incremental revenue from the US asset presents upside potential for the company’s full-year 2026 revenue growth guidance (15%–20%).
- Biosecure Act Policy Catalysts & Long-Term Roadmap:
- Following the anticipated release of designated restricted entities by the US OMB within 2026, non-Chinese CDMOs including Samsung Biologics are positioned to capture expanding market share.
- Long-term manufacturing capacity expansion roadmap targets Plants 6–8 through 2032, with Plant 6 groundbreaking scheduled within 2026.
- The newly secured Bio Campus 3 site will be dedicated to scaling up next-generation CDMO modalities including AXC (ADCs, AOCs) and cell & gene therapy (CGT).
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as a premier global CDMO demonstrating industry-leading profitability through 100% capacity utilization across Plants 1–4, while effectively hedging geopolitical risks via the Maryland site acquisition and positioning itself as a prime beneficiary of order reallocations under the US Biosecure Act. The core perspective prioritizes the upcoming revenue consolidation from the US facility in Q3 leading to potential upward guidance revisions, alongside long-term modality diversification into AXC/CGT via Plant 6 groundbreaking and Bio Campus 3 investments.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual quarterly revenue recognition and margin performance of the Maryland facility starting in Q3, official revisions to annual revenue growth guidance, contract disclosures following Biosecure Act implementation, and the formal groundbreaking timeline for Songdo Plant 6 within the year. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
